首页> 外文OA文献 >Fecal microbiota composition associates with the capacity of human peripheral blood monocytes to differentiate into immunogenic dendritic cells in vitro
【2h】

Fecal microbiota composition associates with the capacity of human peripheral blood monocytes to differentiate into immunogenic dendritic cells in vitro

机译:Fecal Microbiota成分与人外周血单核细胞的能力分化为体外分化为免疫原性树突状细胞

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Although promising for active immunization in cancer patients, dendritic cells (DCs) vaccines generated in vitro display high inter-individual variability in their immunogenicity, which mostly limits their therapeutic efficacy. Gut microbiota composition is a key emerging factor affecting individuals’ immune responses, but it is unknown how it affects the variability of donors’ precursor cells to differentiate into immunogenic DCs in vitro. By analyzing gut microbiota composition in 14 healthy donors, along with the phenotype and cytokines production by monocyte-derived DCs, we found significant correlations between immunogenic properties of DC and microbiota composition. Namely, donors who had higher α-diversity of gut microbiota and higher abundance of short-chain fatty acid (SCFAs) and SCFA-producing bacteria in feces, displayed lower expression of CD1a on immature (im)DC and higher expression of ILT-3, costimulatory molecules (CD86, CD40) proinflammatory cytokines (TNF-α, IL-6, IL-8) and IL-12p70/IL-10 ratio, all of which correlated with their lower maturation potential and immunogenicity upon stimulation with LPS/IFNγ, a well-known Th1 polarizing cocktail. In contrast, imDCs generated from donors with lower α-diversity and higher abundance of Bifidobacterium and Collinsella in feces displayed higher CD1a expression and higher potential to up-regulate CD86 and CD40, increase TNF-α, IL-6, IL-8 production, and IL-12p70/IL-10 ratio upon stimulation. These results emphasize the important role of gut microbiota on the capacity of donor precursor cells to differentiate into immunogenic DCs suitable for cancer therapy, which could be harnessed for improving the actual and future DC-based cancer therapies.
机译:虽然在癌症患者中积极免疫有前途,但在体外产生的树突细胞(DCS)疫苗在其免疫原性中显示出高间间变异性,这主要限制了其治疗效果。 Gut Microbiota组成是影响个体免疫反应的关键新兴因素,但它是如何影响供体前体细胞的变异性在体外分化为免疫原性DC的变化。通过在14个健康供体中分析肠道微生物酵母组合物,随着单核细胞衍生的DCS产生的表型和细胞因子,我们发现DC和微生物酵母组合物的免疫原性之间存在显着的相关性。即,具有较高α-肠道微生物的α-多样性和粪便中的短链脂肪酸(SCFA)和SCFA产生细菌的供体,显示CD1a对未成熟(IM)DC的较低表达和ILT-3的更高表达,共刺激分子(CD86,CD40)促炎细胞因子(TNF-α,IL-6,IL-8)和IL-12P70 / IL-10的比例,所有这些都与其较低的成熟电位和免疫原性与LPS /IFNγ刺激相关是一个众所周知的TH1偏光鸡尾酒。相比之下,从具有较低α-多样性和较高丰度的供体产生的IMDC在粪便中显示出更高的CD1a表达和更高的调节CD86和CD40,增加TNF-α,IL-6,IL-8生产,和IL-12P70 / IL-10在刺激后的比例。这些结果强调了肠道微生物会对供体前体细胞的能力分化成适合于癌症治疗的免疫原性DC的重要作用,这可以利用改善实际和未来的直流癌疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号